皮姆激酶抑制剂:更新的专利审查 (2016年至今)
Anushka Sharma1, Rahul Dubey1, Shankar Gupta1
1Department of Pharmaceutical Chemistry, ISF College of Pharmacy, Moga, India.
Expert opinion on therapeutic patents
|June 6, 2024
概括
皮姆基因酶 (PIM-1,PIM-2,PIM-3) 在细胞信号传递中至关重要,并与淋巴瘤和前列腺癌等癌症有关. 选择性抑制剂在晚期和耐火性癌症中表现有前途.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 药物发现 药物发现 药物发现
背景情况:
- 皮姆基因酶 (PIM-1,PIM-2,PIM-3) 是一种涉及细胞存活,增殖和分化的氨酸/氨酸蛋白基因酶.
- 过度表达PIM激酶与血液性恶性瘤有关,包括扩散性大B细胞淋巴瘤 (DLBCL),多发性骨髓瘤,白血病,淋巴瘤和前列腺癌.
- PIM 激酶代表了精确癌症治疗的有希望的生物标记物和治疗点.
研究的目的:
- 审查PIM激酶在瘤发生中的作用.
- 要突出在2016年至今期间开发的专利PIM激酶抑制剂.
- 为这些抑制剂提供药理和结构洞察力.
主要方法:
- 综合性文献综述,重点关注PIM激酶及其抑制剂.
- 从2016年到现在的专利PIM激酶抑制剂的分析.
- 检查已识别的抑制剂的药理和结构性质.
主要成果:
- 在瘤学中,PIM激酶具有显著的兴趣,特别是在血液恶性瘤中.
- 专利的PIM激酶抑制剂,通常具有异环环结构,在癌症化疗中表现出有前途的结果.
- 针对PIM-1,PIM-2和/或PIM-3的选择性抑制剂在患有晚期,复发或耐火性癌症的患者中已显示出有效性.
结论:
- 在瘤学中,PIM激酶是已验证的治疗点.
- 新型异环PIM激酶抑制剂为有效的癌症治疗策略提供了潜在的潜力.
- 针对PIM异型的制有望为高级癌症的精准医学提供希望.
关键词:
生物标志物生物标志物这种 PIM 激酶是 PIM 激酶.癌症 癌症 癌症 癌症 癌症抑制剂 抑制剂 抑制剂patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent精准医学是一门精准医学.相关概念视频
Phosphoinositides and PIPs
8.5K
Phosphoinositides are a group of phospholipids containing a glycerol backbone with two fatty acid chains and a phosphate attached to a myoinositol sugar ring. The inositol head group extends into the cytoplasm, where it is modified by adding phosphate groups to form phosphatidylinositol phosphates or PIPs.
Different phosphoinositides are synthesized and recruited on the cytosolic face of the plasma membrane. The localization of specific phosphoinositides concentrated in separate membrane...
Different phosphoinositides are synthesized and recruited on the cytosolic face of the plasma membrane. The localization of specific phosphoinositides concentrated in separate membrane...
8.5K
PI3K/mTOR/AKT Signaling Pathway
3.5K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.5K
Protein Kinases and Phosphatases
13.1K
Proteins undergo chemical modifications that trigger changes in the charge, structure, and conformation of the proteins. Phosphorylation, acetylation, glycosylation, nitrosylation, ubiquitination, lipidation, methylation, and proteolysis are various protein modifications that regulate protein activity. Such modifications are usually enzyme-driven.
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...
13.1K
Inhibition of Cdk Activity
4.7K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
157
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
157
M-Cdk Drives Transition Into Mitosis
5.6K
Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
5.6K


